Clinical study on biapenem in respiratory tract infection

Abstract

Biapenem (BIPM), a new carbapenem antibiotic, was administered in ten patients with respiratory ract infection at the dose 600 mg or 1200 mg daily; bacterial pneumonia in 8, mycoplasma pneumonia in 2.
Clinical efficacy were excellent in 3, good in 1, fair in 1, poor in I and unevaluable in 4.
No side effects were observed. A slight and transient elevation of serum OPT level was observed in one patient.
These results suggested that BIPM might be effective and safe in respiratory tract infections.